Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | n/a | -780.0% |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | n/a | 25.0 |
Pr/Book | 1.4 |
Latest | F'cast | |
---|---|---|
Revenue | n/a | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Mar-18 | n/a | (3.03) | (3.23)p | n/a | n/a | n/a | n/a | 0.0% |
31-Mar-19 | n/a | (3.12) | (2.70)p | n/a | n/a | n/a | n/a | 0.0% |
31-Mar-20 | n/a | (3.17) | (2.07)p | n/a | n/a | n/a | n/a | 0.0% |
31-Mar-21 | 0.19 | (3.21) | (1.82)p | n/a | n/a | n/a | n/a | 0.0% |
31-Mar-22 | n/a | (3.17) | (0.99)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Mar-23 | 0.50 | (3.90) | (1.20)p | n/a | n/a | n/a | n/a | 0.0% |
31-Mar-24 | 5.00 | (1.60) | (0.20)p | n/a | n/a | n/a | n/a | 0.0% |
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Clinical trial update | 25-Jan-2023 | 07:00 | RNS |
Grant of Options - Director/PDMR Shareholding | 14-Dec-2022 | 17:08 | RNS |
Half-year Report | 08-Dec-2022 | 07:00 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 4.48p |
Change Today | -0.070p |
% Change | -1.54 % |
52 Week High | 7.10 |
52 Week Low | 2.85 |
Volume | 162,912 |
Shares Issued | 274.89m |
Market Cap | £12.31m |
RiskGrade | 304 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
08:32 | 50,000 @ 4.55p |
08:28 | 212 @ 4.70p |
08:28 | 100 @ 4.30p |
08:27 | 2,600 @ 4.40p |
08:24 | 50,000 @ 4.43p |
CFO | Richard Moulson |
CEO | Huw Jones |
You are here: research